PHARMA

Close to 90% of patients with RA who fail methotrexate, are prescribed tumor factor necrosis inhibitor therapies – like Humira- in a wait-and-see approach that lasts about 3-6 months. But most patients don’t respond to TNFi – forcing them to stay on therapy unnecessarily, while their disease progresses. PrismRA is the first blood test which predicts an inadequate response, so that patients can start other therapies right from the start – or now with expanded use, at any point in their therapeutic journey. PrismRA can reduce the cost of care by more than $19,000 per year per patient by avoiding ineffective therapies they don’t respond to

Research findings from two studies demonstrate the antimicrobial effectiveness of STIMULAN when mixed with antibiotics. STIMULAN is the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue.

Novel technology, based on infrared spectroscopy, can accurately determine identity of pathogens and their susceptibility to antibiotics resistance in 30-40 minutes, directly from urine sample of patients.

Selinexor's novel mechanism of action which is based on the selective inhibition of the nuclear export protein XPO1, is different from that of all  currently approved therapies.

Dr. Marc Engelhardt, Chief Medical Officer, commented: “The Orphan Drug Designation of lisavanbulin by the U.S. FDA is an important milestone for the development of lisavanbulin. Glioblastoma is associated with a poor prognosis and there are only very limited therapeutic options available.

Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute...